EP05.02-013. Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC
Back to course
Pdf Summary
Asset Subtitle
Amanda M Moore
Meta Tag
Speaker Amanda M Moore
Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
Keywords
immune-mediated adverse events
treatment interruptions
treatment discontinuations
durvalumab
unresectable stage III NSCLC
retrospective cohort
pneumonitis
early identification
management
clinicians
Powered By